Arthur Kirsch
Director/Board Member at LIQUIDIA CORPORATION
Net worth: 411 840 $ as of 2024-05-30
Profile
Arthur S.
Kirsch is currently an Independent Director at Liquidia Technologies, Inc., Liquidia Corp., and Anavasi Diagnostics.
He previously served as the President & Chief Executive Officer at Natwest Securities Corp.
from 1990 to 1993, Chairman at POZEN, Inc. from 2015 to 2016, Independent Chairman at Old API Wind-down Ltd.
from 2016 to 2019, and Independent Director at Immunomedics, Inc. from 2015 to 2016.
He also held positions as an Executive Vice President & Head-Equity Division at Drexel Burnham Lambert, Inc. from 1979 to 1990, President at NatWest Securities Ltd.
from 1990 to 1993, Executive Vice President & Head-Research at Vector Securities LLC from 1994 to 2004, and MD, Head-Healthcare Research & Capital Markets at Prudential Vector Healthcare Group from 1999 to 2001.
Mr. Kirsch received his undergraduate degree from the University of Rhode Island and an MBA from Baruch College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
LIQUIDIA CORPORATION
0.04% | 2024-04-25 | 32,000 ( 0.04% ) | 411 840 $ | 2024-05-30 |
Arthur Kirsch active positions
| Companies | Position | Start |
|---|---|---|
| LIQUIDIA CORPORATION | Director/Board Member | 2020-06-27 |
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Director/Board Member | 2016-12-12 |
| Anavasi Diagnostics | Director/Board Member | 2022-11-01 |
Former positions of Arthur Kirsch
| Companies | Position | End |
|---|---|---|
| KADMON HOLDINGS, INC. | Director/Board Member | 2021-10-31 |
| OLD API WIND-DOWN LTD. | Chairman | 2019-05-29 |
| IMMUNOMEDICS, INC. | Director/Board Member | 2016-10-12 |
| POZEN INC. | Chairman | 2016-02-04 |
Vector Securities LLC
 Vector Securities LLC Investment Banks/BrokersFinance Part of Prudential Financial, Inc., Vector Securities LLC is a company that provides investment banking services. The company is based in Deerfield, IL. Vector Securities was acquired by Prudential Securities on June 09, 1999. | Chief Tech/Sci/R&D Officer | 2004-04-30 |
Training of Arthur Kirsch
| University of Rhode Island | Undergraduate Degree |
| Baruch College | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| LIQUIDIA CORPORATION | Health Technology |
| Private companies | 12 |
|---|---|
POZEN, Inc.
 POZEN, Inc. Pharmaceuticals: MajorHealth Technology POZEN, Inc. manufactures and markets pharmaceutical products. Its Pipeline products are PA Product Portfolio, which is focused on integrated aspirin therapies that enable the full power of aspirin by reducing its potential gastrointestinal damage. The firm PA Product Portfolio consists of PA8140 and PA32540. The company was founded by John R. Plachetka in 1996 and is headquartered in Raleigh, NC. | Health Technology |
| Prudential Vector Healthcare Group | Finance |
| Natwest Securities Corp. | |
| Drexel Burnham Lambert, Inc. | Process Industries |
PhysioSonics, Inc.
 PhysioSonics, Inc. Medical DistributorsDistribution Services PhysioSonics, Inc. developed neurological medical devices. The firm offered products such as transcranial doppler and neuromonitor. It also developed ultrasound for automated monitoring of stroke symptoms. The company was founded in 2000 and was headquartered in Bellevue, WA. | Distribution Services |
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Old API Wind-down Ltd.
 Old API Wind-down Ltd. Pharmaceuticals: MajorHealth Technology Aralez Pharmaceuticals Inc. engages in the development, acquisition, and commercialization of cardiovascular, pain, and other product therapies. It operates through the following geographical segments: United States and Canada. The company is founded on December 2, 2015, and is headquartered in Mississauga, Canada. | Health Technology |
Vector Securities LLC
Vector Securities LLC Investment Banks/BrokersFinance Part of Prudential Financial, Inc., Vector Securities LLC is a company that provides investment banking services. The company is based in Deerfield, IL. Vector Securities was acquired by Prudential Securities on June 09, 1999. | Finance |
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
| NatWest Securities Ltd. | Finance |
| Anavasi Diagnostics |
- Stock Market
- Insiders
- Arthur Kirsch
